Nanotechnology and nuclear medicine; research and preclinical applications

Hellenic Journal of Nuclear Medicine

Volumn 14, Issue 2, 2011, Pages

  Assadi, Majid ^a   Afrasiabi, Kolsoom ^a   Nabipour, Iraj ^a   Seyedabadi, Mohammad ^a  

^a BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Nanomedicine Theranostic; Nanotechnology; Nuclear medicine; Quantum dots (QDs); Regenerative medicine

Indexed keywords

ACTINIUM 225; CARBON NANOTUBE; COPPER; DENDRIMER; FLUORINE 18; FLUOROCARBON; FULLERENE; GADOLINIUM; GOLD; GOLD 198; IMMUNOLIPOSOME; INDIUM; IRON OXIDE; LIPOSOME; NANOTUBE; QUANTUM DOT; RADIOISOTOPE; RHENIUM 188; RITUXIMAB; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TECHNETIUM 99M;

ANGIOGENESIS; ATHEROSCLEROTIC PLAQUE; BREAST CANCER; CANCER DIAGNOSIS; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; HUMAN; ISOTOPE LABELING; LUNG CANCER; MEDICAL RESEARCH; MELANOMA; MICROBUBBLE; MICROMETASTASIS; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASM; NUCLEAR MEDICINE; OSTEOARTHRITIS; PERIPHERAL NEUROPATHY; REGENERATIVE MEDICINE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

HUMANS; NANOMEDICINE; NANOTECHNOLOGY; NANOTUBES; NUCLEAR MEDICINE; QUANTUM DOTS; REGENERATIVE MEDICINE; THERAPEUTICS;

EID: 79961156389     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. Hong H, Zhang Y, Sun J et al. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today 2009; 4: 399-413.
2. Edwards SA. The visionries. The nanotech pioneers: Where are they taking us? Weinheim: Wiley-VCH; 2006:15.
3. Smalley RE. Fullerenes, space, and the world's energy challenge. Caneus 2002: Canada-Europe-US-Japan workshop on micro nano technology for aerospace applications. Montreal, Ca 2002.
4. Nanomedicine -An ESF- European Medical Research Councils (EMRC) Forward Look Report. Strasbourg cedex,: European Science Foundation; 2004.
5. Monteiro ML, Swanson RA, Coppeto JR et al. A microangiopathic syndrome of encephalopathy, hearing loss, and retinal arteriolar occlusions. Neurology 1985; 35: 1113-21. (Pubitemid 15003443)
6. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEBJ 2005; 19: 311-30. (Pubitemid 40316520)
7. Pan D, Lanza GM, Wickline SA et al. Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol 2009; 70: 274-85.
8. Ting G, Chang CH, Wang HE et al. Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. J Biomed Biotechnol 2010; 9(5): 35-7.
9. Assadi M, Afrasiabi K. An establishment of nano-nuclear medicine fellowship: is it necessary? Iranian Journal of Nuclear Medicine 2010; 18(Suppl 1): 67.
10. Assadi M, Nabipour I. The role of nanotechnology in nuclear medicine as a limb of molecular medicine with emphasis on medical roadmap of Iran. International congress of nuclear medicine and molecular imaging. Iran; 2009.
11. Nanotechnology. European technology platform on nanomedicine nanotechnology for health 2005 [cited 2010 June 10).
12. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008; 49 Suppl 2: 113S-28S.
13. Singh R, Pantarotto D, Lacerda L et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U SA 2006; 103: 3357-62. (Pubitemid 43346474)
14. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003; 17: 545-80. (Pubitemid 36307540)
15. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2: 683-93. (Pubitemid 37328919)
16. Lee HY, Li Z, Chen K et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 2008; 49: 1371-9.
17. Cai W, Chen X. Nanoplatforms for targeted molecular imaging in living subjects. Small 2007; 3: 1840-54. (Pubitemid 350099850)
18. Michalet X, Pinaud FF, Bentolila LA et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005; 307: 538-44. (Pubitemid 40165671)
19. Medintz IL, Uyeda HT, Goldman ER et al. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005; 4: 435-46. (Pubitemid 40774047)
20. Larson DR, Zipfel WR, Williams RM et al. Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science 2003; 300: 1434-6. (Pubitemid 36638163)
21. Schipper ML, Cheng Z, Lee SW et al. MicroPET-based biodistribution of quantum dots in living mice. J Nucl Med 2007; 48: 1511-8. (Pubitemid 47397401)
22. Wagenaar DJ, Chen JA. Nuclear imaging of vulnerable plaque: contrast improvements through multi-labeling of nanoparticles. Nuclear science symposium conference record, 2005 IEEE. fajardo; 2005: 5pp.-1685.
23. Cormode DP, Skajaa T, van Schooneveld MM et al. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett 2008; 8: 3715-23.
24. Cai W, Chen K, Mohamedali KA et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006; 47: 2048-56. (Pubitemid 47544993)
25. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-35. (Pubitemid 40848295)
26. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2: 91-100. (Pubitemid 37328796)
27. 111In nanoparticles. Int J Cancer 2007; 120: 1951-7. (Pubitemid 46418372)
28. Cai W, Chen K, Li ZB et al. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med 2007; 48: 1862-70. (Pubitemid 350099333)
29. Chen K, Li ZB, Wang H et al. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging 2008; 35: 2235-44.
30. Gao X, Cui Y, Levenson RM et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004; 22: 969-76. (Pubitemid 39014473)
31. Lim YT, Kim S, Nakayama A et al. Selection of quantum dot wavelengths for biomedical assays and imaging. Mol Imaging 2003; 2: 50-64.
32. Jackson H, Muhammad O, Daneshvar H et al. Quantum dots are phagocytized by macrophages and colocalize with experimental gliomas. Neurosurgery 2007; 60: 524-9; discussion 529-30.
33. Debbage P, Jaschke W. Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem Cell Biol 2008; 130: 845-75.
34. Reilly RM. Biomolecules as targeting vehicles for in situ radiotherapy of malignancies. modern biopharmaceuticals: designe, development and optimization, Ed. Knaeblein J. Vol. 2. 2005, Weinheim, Germany: Wiley-VCH.
35. Mitra A, Nan A, Line BR et al. Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des 2006; 12: 4729-49. (Pubitemid 44841764)
36. Hamoudeh M, Kamleh MA, Diab R et al. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008; 60: 1329-46.
37. Pantarotto D, Singh R, McCarthy D et al. Functionalized carbon nanotubes for plasmid DNA gene delivery. Angew Chem Int Ed Engl 2004; 43: 5242-6. (Pubitemid 39382552)
38. Pantarotto D, Briand JP, Prato M et al. Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem Commun (Camb) 2004; 16-7. (Pubitemid 38121939)
39. Kam NW, O'Connell M, Wisdom JA et al. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci U SA 2005; 102(11): 600-5.
40. Reilly RM. Carbon nanotubes: potential benefits and risks of nanotechnology in nuclear medicine. J Nucl Med 2007; 48: 1039-42. (Pubitemid 47052639)
41. Reilly R. The immunoreactivity of radiolabeled antibodies-its impact on tumor targeting and strategies for preservation. Cancer Biother Radiopharm 2004; 19: 669-72. (Pubitemid 40279576)
42. 188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas. Eur J Nucl Med Mol Imaging 2008; 35: 1838-46.
43. McDevitt MR, Chattopadhyay D, Kappel BJ et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 2007; 48: 1180-9.
44. Lucignani G. Nanoparticles for concurrent multimodality imaging and therapy: the dawn of new theragnostic synergies. Eur J Nucl Med Mol Imaging 2009; 36: 869-74.
45. Pastorin G, Wu W, Wieckowski S et al. Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun (Camb) 2006; 1182-4. (Pubitemid 43345208)
46. Kim G, O'Regan R, Nie S. Biomedical nanotechnology for molecular imaging, profiling, and drug targeting. Conf Proc IEEE Eng Med Biol Soc 2005; 1: 714-6.
47. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) 2008; 3: 703-17.
48. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med 2005; 46: 1210-8. (Pubitemid 43741084)
49. 111In-ChL6 nanoparticle AMF-induced thermoablative therapy for human breast cancer in mice. J Nucl Med 2007; 48: 437-44. (Pubitemid 47604930)
50. Flexman JA, Cross DJ, Lewellen BL et al. Magnetically targeted viral envelopes: a PET investigation of initial biodistribution. IEEE Trans Nanobioscience 2008; 7: 223-32.
51. Wickline SA, Neubauer AM, Winter PM et al. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007; 25: 667-80. (Pubitemid 46516717)
52. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol 2001; 38: 177-92. (Pubitemid 32448027)
53. Ross PE. Viral nano electronics. Sci Am 2006; 295: 52-5.
54. Lee SW, Mao C, Flynn CE et al. Ordering of quantum dots using genetically engineered viruses. Science 2002; 296: 892-5. (Pubitemid 34464891)
55. Muneoka K, Allan CH, Yang X et al. Mammalian regeneration and regenerative medicine. Birth Defects Res C Embryo Today 2008; 84: 265-80.
56. Solanki A, Kim JD, Lee KB. Nanotechnology for regenerative medicine: nanomaterials for stem cell imaging. Nanomedicine (Lond) 2008; 3: 567-78.
57. Rosen AB, Kelly DJ, Schuldt AJ et al. Finding fluorescent needles in the cardiac haystack: tracking human mesenchymal stem cells labeled with quantum dots for quantitative in vivo three-dimensional fluorescence analysis. Stem Cells 2007; 25: 2128-38. (Pubitemid 47258192)
58. Jaiswal JK, Mattoussi H, Mauro JM et al. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol 2003; 21: 47-51. (Pubitemid 36055826)
59. Wu X, Liu H, Liu J et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003; 21: 41-6. (Pubitemid 36055825)
60. Bulte JW, Kraitchman DL. Monitoring cell therapy using iron oxide MR contrast agents. Curr Pharm Biotechnol 2004; 5: 567-84. (Pubitemid 39654853)
61. Corot C, Robert P, Idee JM et al. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006; 58: 1471-504. (Pubitemid 44820503)
62. Zhu J, Zhou L, XingWu F. Tracking neural stem cells in patients with brain trauma. N Engl J Med 2006; 355: 2376-8. (Pubitemid 44837805)
63. Kraitchman DL, Heldman AW, Atalar E et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 2003; 107: 2290-3. (Pubitemid 36578497)
64. Li X, Liu X, Dong W et al. In vitro evaluation of porous poly(L-lactic acid) scaffold reinforced by chitin fibers. J Biomed Mater Res B Appl Biomater 2009; 90: 503-9.
65. Hwang do W, Jang SJ, Kim YH et al. Real-time in vivo monitoring of viable stem cells implanted on biocompatible scaffolds. Eur J Nucl Med Mol Imaging 2008; 35: 1887-98.
66. Park KI, Teng YD, Snyder EY. The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. Nat Biotechnol 2002; 20: 1111-7. (Pubitemid 35285439)
67. Del Vecchio S, Zannetti A, Fonti R et al. Nuclear imaging in cancer theranostics. Q J Nucl Med Mol Imaging 2007; 51: 152-63. (Pubitemid 47064656)
68. Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomedicine (Lond) 2008; 3: 137-40. (Pubitemid 351611851)
69. 111In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res 2005; 11: 7087s-7092s.
70. 64Cu-labeled magnetic nanoparticles for multimodal imaging. Bioconjug Chem 2008; 19: 1496-504. (Pubitemid 352032352)
71. Choi JS, Park JC, Nah H et al. A hybrid nanoparticle probe for dual-modality positron emission tomography and magnetic resonance imaging. Angew Chem Int Ed Engl 2008; 47: 6259-62.
72. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003; 22: 6524-36. (Pubitemid 37372332)
73. 18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem 2009; 20: 397-401.
74. Tran TD, Caruthers SD, Hughes M et al. Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. Int J Nanomedicine 2007; 2: 515-26.
75. Wang H, Wang J, Deng X et al. Biodistribution of carbon single-wall carbon nanotubes in mice. J Nanosci Nanotechnol 2004; 4: 1019-24. (Pubitemid 40056461)
76. Balasubramanian K, Burghard M. Chemically functionalized carbon nanotubes. Small 2005; 1: 180-92.
77. Lacerda L, Bianco A, Prato M et al. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv Drug Deliv Rev 2006; 58: 1460-70. (Pubitemid 44822607)
78. Liu Z, Cai W, He L et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007; 2: 47-52. (Pubitemid 46210038)
79. McDevitt MR, Chattopadhyay D, Jaggi JS et al. PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS One 2007; 2: e907.
80. Liu Z, Chen K, Davis C et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008; 68: 6652-60.
81. Joshi BP, Wang TD. Exogenous Molecular Probes for Targeted Imaging in Cancer: Focus on Multi-modal Imaging. Cancers 2010; 2: 1251-87.
82. Pelley JL, Daar AS, Saner MA. State of academic knowledge on toxicity and biological fate of quantum dots. Toxicol Sci 2009; 112: 276-96.
83. Kennel SJ, Woodward JD, Rondinone AJ et al. The fate of MAb-targeted Cd(125m)Te/ZnS nanoparticles in vivo. Nucl Med Biol 2008; 35: 501-14.
84. Cai W, Shin DW, Chen K et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006; 6: 669-76.
85. Bentolila LA, Ebenstein Y, Weiss S. Quantum dots for in vivo small-animal imaging. J Nucl Med 2009; 50: 493-6.
86. 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005; 46: 1707-18. (Pubitemid 46211595)
87. Mulder WJ, Cormode DP, Hak S et al. Multimodality nanotracers for cardiovascular applications. Nat Clin Pract Cardiovasc Med 2008; 5 Suppl 2: S103-11.
88. Duconge F, Pons T, Pestourie C et al. Fluorine-18-labeled phospholipid quantum dot micelles for in vivo multimodal imaging from whole body to cellular scales. Bioconjug Chem 2008; 19: 1921-6.
89. Kim S, Lim YT, Soltesz EG et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004; 22: 93-7. (Pubitemid 38057962)
90. Inoue Y, Izawa K, Yoshikawa K et al. In vivo fluorescence imaging of the reticuloendothelial system using quantum dots in combination with bioluminescent tumour monitoring. Eur J Nucl Med Mol Imaging 2007; 34: 2048-56. (Pubitemid 350212143)
91. Boerman OC, Laverman P, Oyen WJ et al. Radiolabeled liposomes for scintigraphic imaging. Prog Lipid Res 2000; 39: 461-75.
92. Ogihara-Umeda I, Sasaki T, Kojima S et al. Optimal radiolabeled liposomes for tumor imaging. J Nucl Med 1996; 37: 326-32. (Pubitemid 26150911)
93. Phillips WT. Delivery of gamma-imaging agents by liposomes. Adv Drug Deliv Rev 1999; 37: 13-32. (Pubitemid 29164497)
94. Dagar S, Krishnadas A, Rubinstein I et al. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release 2003; 91: 123-33. (Pubitemid 37288883)
95. Harrington KJ, Mohammadtaghi S, Uster PS et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001; 7: 243-54. (Pubitemid 32183025)
96. Harrington KJ, Lewanski CR, Stewart JS. Liposomes as vehicles for targeted therapy of cancer. Part 1: preclinical development. Clin Oncol (R Coll Radiol) 2000; 12: 2-15. (Pubitemid 30150769)
97. 18F-radiolabeling preformed liposomes and determination of liposomal trafficking by positron emission tomography. J Med Chem 2007; 50: 6454-7. (Pubitemid 350309083)
98. Oku N. Delivery of contrast agents for positron emission tomography imaging by liposomes. Adv Drug Deliv Rev 1999; 37: 53-61. (Pubitemid 29164499)
99. 18F-FDP). Nucl Med Biol 2007; 34: 165-71. (Pubitemid 46241896)
100. 177Lu-pegylated liposomes conjugates in tumor-bearing mice. Nuclear Instruments and Methods in Physics Research A 2006; 569: 533-7. (Pubitemid 44820481)
101. 111In-VNB-liposome on human colorectal adenocarcinoma HT-29/luc mouse xenografts. Nucl Instrum and Methods in Physics Res A 2006; 596: 497-504. (Pubitemid 44820476)
102. 64Cu for positron emission tomography (PET) imaging. Bioconjug Chem 2008; 19: 2577-84.
103. Elbayoumi TA, Pabba S, Roby A et al. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res 2007; 17: 1-14. (Pubitemid 46631140)
104. Elbayoumi TA, Torchilin VP. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med MoI Imaging 2006; 33: 1196-205. (Pubitemid 44484476)
105. 111In-labeled polychelating-polymer- containing immunoliposomes. Mol Pharm 2006; 3: 525-30. (Pubitemid 44639129)
106. Line BR, Mitra A, Nan A et al. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 2005; 46: 1552-60. (Pubitemid 46173267)
107. Almutairi A, Rossin R, Shokeen M et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci USA 2009; 106: 685-90.
108. Emfietzoglou D, Kostarelos K, Sgouros G. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 2001; 42: 499-504. (Pubitemid 32207403)
109. Seymour L, Eisenhauer E. A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity. Cancer Chemother Pharmacol 2001; 47: 2-10. (Pubitemid 32664505)
110. Kostarelos K, Emfietzoglou D. Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals. Anticancer Res 2000; 20: 3339-45.
111. Hallahan D, Geng L, Qu S et al. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 2003; 3: 63-74. (Pubitemid 37443891)
112. Chen J, Wu H, Han D et al. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett 2006; 231: 169-75. (Pubitemid 43038727)
113. Mougin-Degraef M, Bourdeau C, Jestin E et al. Doubly radiolabeled liposomes for pretargeted radioimmunotherapy. Int J Pharm 2007; 344: 110-7. (Pubitemid 47495979)
114. Syme AM, McQuarrie SA, Middleton JW et al. Dosimetric model for intraperitoneal targeted liposomal radioimmunotherapy of ovarian cancer micrometastases. Phys Med Biol 2003; 48: 1305-20. (Pubitemid 36700466)
115. Emfietzoglou D, Kostarelos K, Papakostas A et al. Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody. J Nucl Med 2005; 46: 89-97. (Pubitemid 43086002)
116. Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control 2002; 9: 106-13.
117. Stein R, Chen S, Haim S et al. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. Cancer 1997; 80: 2636-41. (Pubitemid 28009520)
118. 90Y- labeled nanoparticles. Int J Radiat Oncol Biol Phys 2004; 58: 1215-27. (Pubitemid 38314807)
119. 186Re- liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model. Clin Cancer Res 2008; 14: 3975-83.
120. Phillips WT, Klipper R, Goins B. Novel method of greatly enhanced delivery of liposomes to lymph nodes. J Pharmacol Exp Ther 2000; 295: 309-13.
121. 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis. J Drug Target 2008; 16: 626-37.
122. 188Re-(DXR)-liposome for internal radiotherapy. Cancer Biother Radiopharm 2008; 23: 749-58.
123. 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res 2007; 27: 2217-25.
124. 188Re-DXR-liposome in C26 colon carcinoma ascites mice model. Nucl Med Biol 2008; 35: 883-93.
125. Hamoudeh M, Fessi H, Mehier H et al. Dirhenium decacarbonyl-loaded PLLA nanoparticles: influence of neutron irradiation and preliminary in vivo administration by the TMT technique. Int J Pharm 2008; 348: 125-36. (Pubitemid 350278552)
126. Chunfu Z, Jinquan C, Duanzhi Y et al. Preparation and radiolabeling of human serum albumin (HSA)-coated magnetite na- noparticles for magnetically targeted therapy. Appl Radiat Isot 2004; 61: 1255-9. (Pubitemid 39248946)
127. Hafeli UO. Magnetically modulated therapeutic systems. Int J Pharm 2004; 277: 19-24. (Pubitemid 38670417)
128. Liang S, Wang Y, Yu J et al. Surface modified superparamagnetic iron oxide nanoparticles: as a new carrier for bio-magnetically targeted therapy. J Mater Sci Mater Med 2007; 18: 2297-302.
129. 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol 2008; 35: 623-34.
130. 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model. Cancer Biother Radiopharm 2009; 24: 453-60.
131. 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 2007; 34: 415-23.
132. Chow TH, Lin YY, Hwang JJ et al. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model. Anticancer Res 2009; 29: 2111-20.
133. 225Ac in rigid liposomes for potential targeted therapy of micrometastases. Bioconjug Chem 2008; 19: 1274-82. (Pubitemid 351874951)
134. Sofou S, Kappel BJ, Jaggi JS et al. Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers. Bioconjug Chem 2007; 18: 2061-7. (Pubitemid 350220009)
135. Sofou S, Thomas JL, Lin HY et al. Engineered liposomes for potential alpha-particle therapy of metastatic cancer. J Nucl Med 2004; 45: 253-60. (Pubitemid 47618645)
136. Henriksen G, Schoultz BW, Michaelsen TE et al. Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl Med Biol 2004; 31: 441-9. (Pubitemid 38490743)
137. Nakamura H, Ueno M, Ban HS et al. Development of boron nanocapsules for neutron capture therapy. Appl Radiat Isot 2009; 67: S84-7.
138. Yanagie H, Maruyama K, Takizawa T et al. Application of boron-entrapped stealth liposomes to inhibition of growth of tumour cells in the in vivo boron neutron-capture therapy model. Biomed Pharmacother 2006; 60: 43-50. (Pubitemid 41821218)
139. 111In-VNB-liposome on human colorectal adenocarcinoma HT-29/luc mouse xenografts. Nuclear Instruments and Methods in Physics Research A 2006; 569: 497-504. (Pubitemid 44820476)
140. 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model. Nucl Med Biol 37: 95-104.
141. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 1998; 36: 91-102.
142. Pan X, Wu G, Yang W et al. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem 2007; 18: 101-8. (Pubitemid 46145999)
143. Shukla S, Wu G, Chatterjee M et al. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug Chem 2003; 14: 158-67. (Pubitemid 36169029)
144. 111In. J Nucl Med 2009; 50: 582-90.
145. 198Au0] radioactive composite nanodevices and their use for nanobrachytherapy. Nanomedicine 2008; 4: 57-69.